Abstract
Severe COVID-19 illness is associated with intense inflammation, leading to high rates of thrombotic complications that increase morbidity and mortality. Markedly elevated levels of D-dimer with normal fibrinogen levels are the hallmark laboratory findings of severe COVID-19- associated coagulopathy. Prophylaxis against venous thromboembolism is paramount for all hospitalized patients, with more aggressive prophylaxis and screening recommended for patients with D-dimer levels above 3.0 μg/mL. Point-of-care ultrasonography is the imaging method of choice for patients at high risk, as it entails minimal risk of exposing providers to the virus.
Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.
MeSH terms
-
Anticoagulants / pharmacology*
-
Betacoronavirus* / pathogenicity
-
Betacoronavirus* / physiology
-
Blood Coagulation / drug effects
-
Blood Coagulation / physiology
-
Blood Coagulation Disorders* / blood
-
Blood Coagulation Disorders* / etiology
-
Blood Coagulation Disorders* / therapy
-
Blood Coagulation Tests / methods
-
COVID-19
-
Chemoprevention / methods
-
Coronavirus Infections* / blood
-
Coronavirus Infections* / physiopathology
-
Coronavirus Infections* / therapy
-
Fibrin Fibrinogen Degradation Products / analysis*
-
Humans
-
Monitoring, Physiologic / methods*
-
Pandemics*
-
Pneumonia, Viral* / blood
-
Pneumonia, Viral* / physiopathology
-
Pneumonia, Viral* / therapy
-
SARS-CoV-2
-
Thrombosis / etiology
-
Thrombosis / prevention & control
Substances
-
Anticoagulants
-
Fibrin Fibrinogen Degradation Products
-
fibrin fragment D